0N5A Stock Overview
Develops, manufactures, and markets trauma products for orthopedics. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
aap Implantate AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €2.02 |
52 Week High | €2.88 |
52 Week Low | €1.15 |
Beta | -0.36 |
11 Month Change | 8.02% |
3 Month Change | 53.03% |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -74.43% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
0N5A | GB Medical Equipment | GB Market | |
---|---|---|---|
7D | 3.1% | -0.2% | 2.2% |
1Y | n/a | -2.4% | 8.8% |
Return vs Industry: Insufficient data to determine how 0N5A performed against the UK Medical Equipment industry.
Return vs Market: Insufficient data to determine how 0N5A performed against the UK Market.
Price Volatility
0N5A volatility | |
---|---|
0N5A Average Weekly Movement | n/a |
Medical Equipment Industry Average Movement | 6.3% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 10.2% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0N5A's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 0N5A's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1990 | 111 | Rubino Di Girolamo | www.aap.de |
aap Implantate AG develops, manufactures, and markets trauma products for orthopedics. It offers LOQTEQ, an anatomical plating system for fracture treatment of ankle joint, knee, elbow, wrist, and shoulder; and straight plates and cannulated screws. The company sells its products directly to hospitals, purchasing groups, and hospital groups in Germany through a network of distributors.
aap Implantate AG Fundamentals Summary
0N5A fundamental statistics | |
---|---|
Market cap | €22.40m |
Earnings (TTM) | -€2.31m |
Revenue (TTM) | €11.96m |
1.9x
P/S Ratio-9.7x
P/E RatioIs 0N5A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0N5A income statement (TTM) | |
---|---|
Revenue | €11.96m |
Cost of Revenue | €1.47m |
Gross Profit | €10.49m |
Other Expenses | €12.80m |
Earnings | -€2.31m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.21 |
Gross Margin | 87.72% |
Net Profit Margin | -19.32% |
Debt/Equity Ratio | 8.1% |
How did 0N5A perform over the long term?
See historical performance and comparison